Aspacytarabine hydrochloride is under clinical development by Ayala Pharmaceuticals and currently in Phase II for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Refractory Acute Myeloid Leukemia have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Aspacytarabine hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Aspacytarabine hydrochloride overview
Aspacytarabine is under development for the treatment of relapsed and refractory acute myeloid leukemia (AML), myelodysplastic syndromes, acute lymphocytic leukemia (ALL). It is administered through the intravenous route. Astarabine is a prodrug which is a conjugate of the cytarabine and the amino acid asparagine. The drug candidate is developed based on Seek to Destroy Only Target technology (S2DOT ). It acts by targeting DNA polymerase. It was under development for the treatment of chronic myelocytic leukemia (CML) and non-Hodgkin lymphoma (NHL).
Ayala Pharmaceuticals overview
Ayala Pharmaceuticals (Ayala) formerly Advaxis Inc (Advaxis) is a biotechnology company that focuses on the discovery, development, and commercialization of multiple cancer immunotherapies. The company develops immunotherapies based on its proprietary Lm Technology, an antigen delivery platform that activates the immune system naturally. The Lm technology uses bioengineered live attenuated Listeria monocytogenes (Lm) bacteria to stimulate cancer-fighting T cells directed against a cancer antigen. Its immunotherapy candidates are intended for the treatment of neoantigen-directed therapies, prostate cancer, and human papilloma virus-associated cancers. The company has partnerships with various biopharmaceutical companies to develop and commercialize proprietary cancer immunotherapies. Ayala is headquartered in Monmouth Junction, New Jersey, the US.
For a complete picture of Aspacytarabine hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
